U-M researchers identify a small molecule that inhibits protein involved in cancer
3/14/2005 Ann Arbor, MI Shaomeng Wang, Ph.D., Proceedings of the National Academy of Sciences (advanced online edition) Researchers have discovered a small molecule that could be the first step in developing a new drug that may one day be able to treat multiple types of cancer. The study, published this week in the advanced online edition of the Proceedings of the National Academy of Sciences, identifies a small molecule that inhibits in cell cultures a protein involved in multiple types of cancer. The protein, called Stat3, is constantly activated in some but not all tumors and has been identified in breast cancer, prostate cancer, ovarian cancer and head and neck cancer. It contributes to new cancer cells growing and prevents cancer cells from dying. It's associated with poorer prognosis for patients since traditional chemotherapy treatments cannot shut down this protein. That's what makes it such an attractive target for new drug development, researchers say. In this new study, researchers at the University of Michigan Comprehensive Cancer Center discovered a molecule called STA-21 blocked Stat3 activity in human breast cancer cells, stopping cancer cells from growing and allowing them to die. “We now can use this compound as a starting point to develop a new class of anti-cancer drugs to target cancer cells with constantly activated Stat3. One of the promises of molecular target drugs like this is they will work in many types of tumors where Stat3 protein is constantly activated. While our work looked specifically at breast cancer cells, [...]